Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
Author:
Tudor Ciuleanu,Lilia Stelmakh,Saulius Cicenas,Skaidrius Miliauskas,Alexandru Calin Grigorescu,Carina Hillenbach,Hrefna Kristin Johannsdottir,Barbara Klughammer,Emilio Esteban Gonzalez
Publication:
The Lancet Oncology
Copyright © 2012 Elsevier Ltd. All rights reserved.